» Articles » PMID: 17068012

Use of MR Spectroscopy and Functional Imaging in the Treatment Planning of Gliomas

Overview
Journal Br J Radiol
Specialty Radiology
Date 2006 Oct 28
PMID 17068012
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Routine anatomical imaging with CT and MRI does not reliably indicate the true extent or the most malignant areas of gliomas and cannot identify the functionally critical parts of the brain. The aim of the study was to see if the use of MR spectroscopic imaging (MRSI) along with functional MRI (fMRI) can better define both the target and the critical structures to be avoided to improve radiation delivery in gliomas. 12 patients with gliomas underwent multivoxel MRS and functional imaging using GE processing software. The choline to creatine ratio (Cho:Cr), which represents the degree of abnormality for each individual voxel on MRSI, was derived, converted into a grayscale grading system, fused to the MRI images and then transferred to the planning CT images. An intensity-modulated radiation therapy (IMRT) plan was developed using the dose constraints based on both the anatomical and the functionally critical regions. Cho:Cr consistently identified the gross tumour volume (GTV) within the microscopic disease (clinical target volume, CTV) and allowed dose painting using IMRT. No correlation between MRSI based Cho:Cr > or =2 and MR defined CTV nor their location was noted. However, MRSI defined Cho:Cr > or =3 was smaller by 40% compared with post-contrast T1 weighted MRI defined GTV volumes. fMRI helped in optimizing the orientation of the beams. In conclusion, both MRSI and fMRI provide additional information to conventional imaging that may guide dose painting in treatment planning of gliomas. A Phase I IMRT dose intensification trial in gliomas using this information is planned.

Citing Articles

Role of Advanced Magnetic Resonance Imaging in Differentiating among Glioma Subtypes and Predicting Tumor-Proliferative Behavior.

Ganesan G, Rangasami R, Chandrasekharan A, Marreddy S, Ramachandran R Asian J Neurosurg. 2025; 20(1):34-42.

PMID: 40041591 PMC: 11875706. DOI: 10.1055/s-0044-1790508.


Conference Report: Review of Clinical Implementation of Advanced Quantitative Imaging Techniques for Personalized Radiotherapy.

Vinogradskiy Y, Bahig H, Bucknell N, Buchsbaum J, Shu H Tomography. 2024; 10(11):1798-1813.

PMID: 39590941 PMC: 11598114. DOI: 10.3390/tomography10110132.


The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma.

Rejimon A, Ramesh K, Trivedi A, Huang V, Schreibmann E, Weinberg B Tomography. 2024; 10(3):428-443.

PMID: 38535775 PMC: 10975697. DOI: 10.3390/tomography10030033.


Integrating multi-modal imaging in radiation treatments for glioblastoma.

Breen W, Aryal M, Cao Y, Kim M Neuro Oncol. 2024; 26(12 Suppl 2):S17-S25.

PMID: 38437666 PMC: 10911793. DOI: 10.1093/neuonc/noad187.


A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma.

Ramesh K, Huang V, Rosenthal J, Mellon E, Goryawala M, Barker P Tomography. 2023; 9(1):362-374.

PMID: 36828381 PMC: 9964256. DOI: 10.3390/tomography9010029.